Medicine

Extended search

 

Matches

A novel biomarker for a reliable diagnosis of colorectal cancer based on differentially methylated genomic regions

Ref.-Nr.: 0301-4550-LI

Medicine : Diagnostics

With approximately 600,000 deaths annually colorectal cancer (CRC) is one of the most common cancer types worldwide. Early cancer and pre-cancer (polyps) detection by colonoscopy over the age of 50 until now is the best strategy for disease control and the chance of the cancer to be curable. Epigenetic changes such as DNA methylation has been shown to occur already at early stages of tumor development making such differentially methylated regions (DMRs) highly attractive for biomarker development ...

A novel inhibitor targeting matrix accumulation in cancer

Ref.-No.: 0105-5855_1-IKF

Medicine : Therapeutics
Medicine : Animal Models
Nucleic Acid-, Protein and Cell-related Technologies

Cancer remains a major health burden and is the second leading cause of death globally (WHO). The microenvironment of cancer cells plays an important role in disease progression. In particular, the composition of the extracellular matrix regulates angiogenesis, cell proliferation, differentiation, cell survival and apoptosis. Dysregulation and accumulation of the extracellular matrix promotes cellular transformation and metastasis leading to cancer progression. A better understanding of the role ...

Alpha-defensins (HNPs) Effectively Inhibit Anthrax-related Toxemia

Ref.-Nr.: 0305-3252-LI

Medicine : Therapeutics

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. B.anthracis can cause human disease via the gastrointestinal, cutaneous or inhalational routes. There is still a considerably high rate of mortality from inhalational anthrax of up to 75 percent, even though fluorquinolone class antibiotics (e.g., ciprofloxacin) are being administered as a first-line therapy. This strategy, in addition, is being threatened by the spread of plasmid-mediated ...

Application of novel channelrhodopsins: molecular engineering, site-specific opsin targeting, discovery of new variants and the advancement in optogenetic devise development

Ref.-No.: 0601-4259-MG

Processes and Methods (incl. Screening) : Life Sciences-HTS/HCS
Medicine : Therapeutics
Research Tools : Other
Nucleic Acid-, Protein and Cell-related Technologies : Cell related

The development of the cation channel channelrhodopsin-2 (ChR2) from Chlamydomonas reinhardtii by Prof. Ernst Bamberg and his colleagues and its application to light-induced modulation of neurons paved the way for the field of optogenetics.
Over time the light-gated cation channel channelrhodopsin-2 (ChR2) has become an indispensable tool in neuroscience. Based on the pioneering work on ChR2 new variants have emerged, differing in their spectrum of light absorption, their kinetic ...

Broad-spectrum vector-based antiviral and potential live vaccine

Ref.-No.: 1402-5459-LC

Medicine
Nucleic Acid-, Protein and Cell-related Technologies

Our scientists developed a vector-based high tolerable and efficient antiviral (plasmid-derived defective interfering particles) to support IAV pandemic preparedness. The DIP also shows a broad-spectrum antiviral activity against other respiratory viruses, e.g. RSV and SARS-CoV-2 and is Intended for intranasal administration (droplet spray) for human use. A state-of-the-art, high-yield production process in a GMP-ready controlled and sterile environment in animal cell culture.

Compounds modulating frameshifting efficiency for antiviral therapy against HIV-1, SARS-CoV-2 and alphaviruses

Ref.-No.: 0707-5639-MG

Medicine : Therapeutics
Medicine : Vaccines

Many viruses use programmed ribosome frameshifting (FS) to increase genome-coding capacity and to regulate the stoichiometric ratio between viral proteins. Among them are human-pathogenic viruses HIV-1, SARS-CoV-2 and alphaviruses such as Semliki Forest virus (SFV). Synthesis of two major HIV-1 genes, gag and pol, requires –1FS. The ratio between Gag and Gag-Pol is crucial for virus propagation and its dysregulation is detrimental for replication, particle formation and infectivity of HIV-1. ...

Dual Inhibition of plexin-B1 and plexin-B2

Ref.-No.: 0603-5770-IKF

Medicine : Therapeutics

A novel molecular target of the semaphorin-plexin system to develop treatment options for cancer and for osteoporosis.

f-Chrimson and vf-Chrimson, two ultrafast variants of the red-light activated channelrhodopsin Chrimson

Ref.-No.: 0601-5208-MG

Processes and Methods (incl. Screening) : Life Sciences-HTS/HCS
Medicine : Therapeutics
Research Tools : Other
Nucleic Acid-, Protein and Cell-related Technologies : Cell related

The development of the cation channel channelrhodopsin-2 (ChR2) from Chlamydomonas reinhardtii by Prof. Ernst Bamberg and his colleagues, and its application to light-induced modulation of neurons paved the way for the field of optogenetics.
Over time the light-gated cation channel channelrhodopsin-2 (ChR2) has become an indispensable tool in neuroscience. Based on the pioneering work on ChR2 new variants have emerged, differing in their spectrum of light absorption, their kinetic ...

FFA2 (GPR43) and FFA3 (GPR41) as novel targets for antidiabetic therapies

Ref.-No.: 0603-4987-IKF

Medicine : Therapeutics
Medicine : Animal Models
Nucleic Acid-, Protein and Cell-related Technologies : Protein related

A double KO, a conditional KO as well as single KO mouse models for FFA2 and FFA3 (free fatty acid receptors 2 and 3), novel targets for diabetes therapies.

Genome-Editing-Technologies - Cas9 double mutant with improved specificity compared to wild-type

Ref.-No.: 0306-5787-LI

Processes and Methods (incl. Screening)
Medicine
Research Tools
Nucleic Acid-, Protein and Cell-related Technologies

The RNA-programmable DNA-endonuclease Cas9 is widely used for genome engineering, where a high degree of specificity is required. Though this is a mechanism well controlled by canonical base-pairing, there is evidence that Cas9 does accept mismatches under certain circumstances.
This might be seen as a threat to precision needed in genome engineering at least in environments where such high precision is ultimately needed and acceptance of mismatches needs to be avoided, e.g.: cellular gene ...

Genome-Editing-Technologies - Single compound or compound mix dramatically improve Homology-Directed-Repair (HDR)

Ref.-No.: 1306-5734-LI & 1306-5288-LI

Processes and Methods (incl. Screening)
Medicine
Research Tools
Nucleic Acid-, Protein and Cell-related Technologies

Precise genome editing demands for homology-directed repair (HDR) by aiming to introduce a new double stranded DNA substituting for a homologous sequence but partially defect one. This substrate dependent reaction does compete with direct non-homologous end joining (NHEJ) of the double strand breaks. NHEJ is error-prone and is therefor mainly used for gene inactivation.
The rate of NHEJ is directly limiting the rate of HDR. For this reason HDR in vitro does occur on a very low level only and ...

GOLD gRNA - allows robust genome editing regardless of spacer sequence composition by super stable hairpin technology

Ref.-No.: 1306-6101-LI

Processes and Methods (incl. Screening)
Medicine
Research Tools
Nucleic Acid-, Protein and Cell-related Technologies

A Cas nuclease such as Cas9 can introduce a DNA double strand break in a sequence target that is complementary to a 20-nt spacer sequence of its bound guide RNA (gRNA) when a protospacer adjacent motif (PAM) is present. The gRNA can be provided as duplex of spacer containing CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA). Or as a single gRNA (sgRNA) where crRNA and tracrRNA are fused by an artificial loop.
Hence a gRNA consists of the target-specific spacer and a constant part typically ...

LITESEC - Light-controlled protein delivery into eukaryotic cells with high spatial and temporal resolution

Ref.-No.: 0706-5707-IKF

Processes and Methods (incl. Screening) : Life Sciences-HTS/HCS
Medicine : Drug delivery
Nucleic Acid-, Protein and Cell-related Technologies : Protein related

The LITESEC-T3SS (Light-induced translocation of effectors through sequestration of endogenous components of the T3SS) system represents a novel, fast, specific, and reversible method to control protein secretion into eukaryotic cells, enabling various medicinal and biotechnological applications, such as targeted drug delivery for tumor therapy.

Monoclonal Antibody to Detect Neutrophil Extracellular Traps via a Novel Post Translational Histone Modification

Ref.-No.: 0305-5699-LI

Medicine : Therapeutics
Medicine : Diagnostics
Research Tools : Antibodies

A novel tool to detect and quantify NETs using a molecular feature of NET formation that has never been proposed as a marker for NETs before

Mouse model for mitochondrial diseases

Ref.-No.: 1013-4827-IKF

Medicine : Animal Models
Research Tools

A tRNAALA heteroplasmy mouse model to study mitochondrial disorders such as encephalomyophathies, that recapitulates symptoms as observed in human patients with disease-causing mutation in the same mitochondrial gene.

New cell type promoting osteogenesis in bone

Ref.-No.: 1012-4727-IKF

Medicine : Diagnostics
Nucleic Acid-, Protein and Cell-related Technologies : Cell related

A promising target to develop treatment options for osteoporosis and other disease conditions associated with bone loss

New KDAC assay and selection system

Ref.-No.: 0803-5480-IKF

Analytics
Processes and Methods (incl. Screening) : Life Sciences-HTS/HCS
Medicine : Diagnostics
Nucleic Acid-, Protein and Cell-related Technologies : Protein related

We present an extremely sensitive, reliable and fast novel Lysine deacetylase (KDAC) assay, which can be performed in a continuous format. This novel KDAC assay is based on Firefly luciferase harboring an acetylation on an essential active site lysine, incorporated by genetic code expansion.

We furthermore offer a bacterial selection system that can help engineer KDACs. The selection system uses a reporter enzyme inactivated by lysine modifications at an essential active site residue, thereby ...

Novel 20S proteasome inhibitors

Ref.-No.: 0706-6249-IKF

Medicine

The proteasome is a central component of the protein degradation machinery in eukaryotic cells and plays a role in regulating cell cycle, neoplastic growth and metastasis. Disruption of this degradative process with small molecule inhibitors against one or more catalytic subunits has implications in a number of human diseases such as cancer, inflammation and ischemic stroke and has exposed the proteasome as an important therapeutic target. Three proteasome inhibitors have so far received regulatory ...

Novel biomarker for diagnosis and targeted therapy of Acute Myeloid Leukemia (AML)

Ref.-No.: 0204-6248-MG

Medicine : Diagnostics

New biomarker candidates for diagnostic sub-classification of AML patients with elevated expression of mitochondrial proteins and subsequent targeted therapy with BCL-2 inhibitors like venetoclax and/or agents targeting mitochondrial complex I

Novel Biomarkers for Ageing and Metabolic Health

Ref.-Nr.: 1013-5354-IKF

Analytics
Medicine : Therapeutics
Medicine : Diagnostics
Research Tools : Other
Nucleic Acid-, Protein and Cell-related Technologies : Cell related

Biomarkers of ageing have long been sought after to help assess the biological age and general health status of individuals. Considerable efforts have been invested to identify such biomarkers, including physiologic readouts, metabolic parameters, glycomic profiles and others. Nevertheless, markers with strong predictive power have remained elusive.

Work in model organisms has identified several conserved signaling pathways that extend life span, such as reduced insulin/IGF signaling and ...

Overcoming disease persistence in myeloproliferative neoplasms (MPN) through combinatorial inhibitor treatment

Ref.-No.: 0204-5895-MG

Medicine : Therapeutics

The mRNA processing factor YBX1 is a novel target in Myeloproliferative neoplasms (MPNs), which in an combinatorial inhibitor treatment with JAK inhibitors completely overcomes disease persistance.

Suicide gene-armed oncolytic virus for enhanced cancer treatment

Ref.-No.: 0204-4297-IKF

Medicine

Cancer stands as the second-leading cause of human death worldwide, following closely behind cardiovascular and cerebrovascular diseases, with a prevalence that continues to rise. In particular, hepatocellular carcinoma is a significant health concern, ranking as the third leading cause of cancer-related deaths, and with a rising incidence rate due to increasing levels of cirrhosis and NAFLD/NASH.

Despite recent advancements in cancer therapies, ...

Ultracompact medical ventilation system

Ref.-No.: 0901-6012-WT

Medicine
Sensors, Devices and Components

Comparison of the ventilation unit (left hand side) with a tennis ball.

The invention relates to a new, ultracompact non-invasive medical ventilation system. The BIPAP (Biphasic Positive Airway Pressure) ventilation unit, of size and weight of a tennis ball, is easy to handle and allows low-budget mass production. It can be powered by a rechargeable battery-pack – a great advantage in case of mobile use or damaged/unstable infrastructure leading to frequent blackouts. These benefits, ...

Xenorhodopsin - a new inward-directed proton pump for an alternative optogentic approach

Ref.-No.: 0601-5295-MG

Processes and Methods (incl. Screening) : Life Sciences-HTS/HCS
Medicine : Therapeutics
Research Tools : Other
Nucleic Acid-, Protein and Cell-related Technologies : Cell related

The development of the cation channel channelrhodopsin-2 (ChR2) from Chlamydomonas reinhardtii by Prof. Ernst Bamberg and his colleagues, and its application to light-induced modulation of neurons paved the way for the field of optogenetics.
Over time the light-gated cation channel channelrhodopsin-2 (ChR2) has become an indispensable tool in neuroscience. Based on the pioneering work on ChR2 new variants have emerged, differing in their spectrum of light absorption, their kinetic ...